¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"contralateral antagonist"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral
    ¹Ý´ëÂÊ-, ¸ÂÀºÆí-
  • contralateral hemiplegia
    ¹Ý´ëÂʹݽŸ¶ºñ
  • contralateral sign
    ´ëÃøÂ¡ÈÄ, ¹Ý´ëÂÊ¡ÈÄ
  • antagonist
    1. ´ëÇ×Á¦, ±æÇ×Á¦ 2. ´ëÇ×±Ù
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦, ¾Æµå·¹³¯¸°±æÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×Á¦
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î±æÇ×Á¦
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù(À°)´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»çÁ¦´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    1.´ëÇ×Á¦, ±æÇ×Á¦, 2.´ëÇ×±Ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral antagonist
    ¹Ý´ëÂÊ´ëÇ×±Ù
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral
    ¹Ý´ëÂÊ-, ¸ÂÀºÆí-
  • contralateral hemiplegia
    ¹Ý´ëÂʹݸ¶ºñ
  • contralateral reflex
    ¹Ý´ëÂʹݻç
  • contralateral sign
    ¹Ý´ëÃø¼ºÂ¡ÈÄ, ¹Ý´ëÂÊ´Ù¸®Â¡ÈÄ
  • antagonist
    ´ëÇ×Á¦, ¸Â¹öÆÀÁ¦
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°´ëÇ×Á¦
  • competitive antagonist
    °æÀï´ëÇ×¹°Áú
  • direct antagonist
    Á÷Á¢´ëÇ×±Ù
  • dopaminergic antagonist
    µµÆÄ¹Î´ëÇ×Á¦, µµÆÄ¹Î¸Â¹öÆÀÁ¦
  • ipsilateral antagonist
    °°ÀºÂÊ´ëÇ×±Ù
  • muscarinic antagonist
    ¹«½ºÄ«¸°´ëÇ×Á¦
  • narcotic antagonist
    ¸¶¾à´ëÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±ÙÀ°´ëÇ×Á¦
  • opioid antagonist
    ¾ÆÆíÀ¯»ç¹°Áú´ëÇ×Á¦
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • H2 receptor antagonist
    H2 ¼ö¿ëü ±æÇ×Á¦µé
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(̡˻ËÛ˻̰Ëâ).
  • heavy metal antagonist
    Á߱ݼӱæÇ×¾à(ñìÐÝáÕÑÏù÷å·).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral antagonist
    ¹Ý´ëÃø±æÇ×±Ù
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral
    ´ëÃøÀÇ, Å¸Ãø¼º, ¹Ý´ëÃø, ±³Â÷ÀûÀÎ.
  • contralateral reflex
    (¹Ý)´ëÃø¼º(Óßö°àõÚãÞÒ).
  • contralateral sign
    (¹Ý)´ëÃø¼º ¡ÈÄ(¡­ó£ý¦).
  • contralateral synergist
    ¹Ý´ëÃøÇùµ¿±Ù, ¹Ý´ëÃø°øµ¿±Ù
  • adrenergic antagonist
    ¾Æµå·¹³¯¸° ±æÇ×¹°Áú
  • adrenergic antagonist
    ¾Æµå·¹³¯¸°¼º ±æÇ×Á¦
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic antagonist
    ¾ËÆÄ¾Æµå·¹³¯¸°±æÇ×Á¦
  • androgen antagonist
    ³²¼ºÈ£¸£¸ó ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú, ±æÇ×±Ù, ±æÇ×¾à.
  • antagonist
    ±æÇ×Á¦
  • associated antagonist
    °ø¾×±æÇ×¹°Áú.
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • beta-adrenergic antagonist
    º£Å¸ ¾Æµå·¹³¯¸°¼º ÀúÇØÁ¦
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦(ÑÏù÷ð¥)
  • cholinergic antagonist
    Äݸ°±æÇ×Á¦(ÑÏù÷ð¥)
  • gibberellin antagonist
    Áö¹ö·¼¸° ±æÇ×Á¦(ÑÏù÷ð¥)
  • irreversible antagonist
    ºñ°¡¿ª ±æÇ×Á¦(ުʦæ½ÑÏù÷ð¥)
  • metabolic antagonist
    ´ë»ç¼º ±æÇ×Á¦(ÓÛÞóàõÑÏùòð¥))
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antagonist
    ±æÇ×Á¦, ±æÇ×¹°Áú
  • contralateral
    ´ëÃøÀÇ, Å¸Ãø¼º, ¹Ý´ëÃø, ±³Â÷ÀûÀÎ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
antag antagonist
CA anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can...
FAA folic acid antagonist; formaldehyde, acetic acid, alcohol
DISC   ; Supratentorial Lesion(brain lesion)½Ã
    --Destructive lesion -...
MLF Median Longitudinal Fasciculus
  Role; links the CN III Nucleus with Contralateral CN ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
control Contralateral
C contralateral
Ant Antagonist
CA calcium antagonist
GnRH-A GnRH antagonist
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • contralateral
    ´ëÃøÀÇ, Å¸Ãø¼º, ¹Ý´ëÃø, ±³Â÷ÀûÀÎ
    ¹Ý´ë¾î=i
  • contralateral body
    ¹Ý´ëÃø ½Åü
  • contralateral hypertrophy
    ´ëμº ºñ´ë
    ´Ù¸¥ ÇÑ ÂÊÀÇ ºñ´ë.
  • contralateral spinal cord
    ¹Ý´ëÃø ô¼ö
  • 5-HT1 receptor antagonist
    5-HT1 ¼ö¿ë±â ±æÇ×Á¦
    ÀÏÂïÀÌ 5-hydroxytry
  • alpha adrenergic antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸° ±æÇ×Á¦
  • antagonist
    ±æÇ×Á¦, ±æÇ× ¹°Áú, ±æÇ×±Ù, ±æÇ× ¾à
    ¹Ý´ë¾î=agonist. µ¿±Ù±ºÀ̳ª ÁÖµÈ ¿îµ¿±Ù¿¡ ¹Ý´ëµÇ´Â ±â´ÉÀ» ÇÏ´Â ±ÙÀ°. ¾à¸®Çп¡¼­´Â ´Ù¸¥ ¾à¹°ÀÇ È¿´ÉÀ» °¨¼Ò½ÃŰ´Â ¾à¹°À̳ª µ¿ÀÏÇÑ ¼ö¿ë±â¸¦ ÀÚ±ØÇÏ¿© »ý¼ºÇÏ´Â ¹°ÁúÀ» ÀǹÌÇÑ´Ù. ´Ù¸¥ ¾à¹°, ¹°ÁúÀÇ ÀÛ¿ëÀ» »ý¹°ÇÐÀû ¹ÝÀÀÀ» À¯µµÇÏÁö ¾Ê°í ¼¼Æ÷ ¸®¼ÁÅÍ¿¡ °áÇÕÇÏ¿©, °¨¾à ¶Ç´Â ¹«È¿·Î ÇÏ´Â ¾à¹°, ¹°Áú.
  • antagonist tooth
    ´ëÇÕÄ¡
  • competitive antagonist
    °æÀï ±æÇ× ¹°Áú
  • enzymic antagonist
    È¿¼Ò ±æÇ×Á¦
  • folic acid antagonist
    ¿±»ê ±æÇ×Á¦
  • hormone antagonist
    Ç×È£¸£¸ó ¾à, Ç×È£¸£¸ó ¹°Áú
  • metabolic antagonist
    ´ë»ç ±æÇ×Á¦
  • narcotic antagonist
    ¸¶¾à ±æÇ×Á¦
  • neuromuscular antagonist
    ½Å°æ±Ù ±æÇ×Á¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
contralateral <anatomy> Pertaining to the opposite side.
(27 Sep 1997)
contralateral partner The corresponding structure on the opposite side.
(05 Mar 2000)
contralateral reflex <clinical sign> A physical examination finding that can indicate inflammation of the meninges (meningitis), performed in two forms: passive flexion of one leg results in a similar movement on the opposite side or if the neck is passively flexed, flexion occurs in the legs.
(27 Sep 1997)
contralateral sign <clinical sign> A physical examination finding that can indicate inflammation of the meninges (meningitis), performed in two forms: passive flexion of one leg results in a similar movement on the opposite side or if the neck is passively flexed, flexion occurs in the legs.
(27 Sep 1997)
aldosterone antagonist An agent that opposes the action of the adrenal hormone aldosterone on renal tubular mineralocorticoid retention; these agents, e.g., spironolactone, are useful in treating the hypertension of primary hyperaldosteronism, or the sodium retention of secondary hyperaldosteronism.
(05 Mar 2000)
antagonist <pharmacology> A substance that tends to nullify the action of another, as a drug that binds to a cell receptor without eliciting a biological response.
Origin: Gr. Antagonistes = an opponent
(18 Nov 1997)
associated antagonist One of two muscles or groups of muscles which pull in nearly opposite directions, but which, when acting together, move the part in a path between their diverging lines of action.
(05 Mar 2000)
beta-adrenoreceptor antagonist A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable.
Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker.
(05 Mar 2000)
calcium antagonist calcium channel-blocking agent
calcium channel antagonist <pharmacology> A class of drugs that act by selective inhibition of calcium ion influx through or across cell membranes or on the release and binding of calcium in intracellular pools.
Calcium channel blockers are used primarily in the treatment of certain heart conditions and stroke. As they are inducers of vascular and other smooth muscle relaxation, they are also used in the treatment of hypertension and cerebrovascular spasms, as myocardial protective agents, and in the relaxation of uterine spasms.
Synonym: calcium antagonist, calcium channel-blocker, slow channel-blocking agent.
(12 May 2002)
mixed opioid agonist-antagonist <pharmacology> A compound that has an affinity for two or more types of opioid receptors and blocks opioid effects on one receptor type while producing opioid effects on a second receptor type.
(13 Nov 1997)
competitive antagonist An antimetabolite.
(05 Mar 2000)
muscarinic antagonist Drugs which bind with muscarinic cholinergic receptors but do not activate them, thus preventing access to acetylcholine; examples include atropine, scopolamine, propantheline, and pirenzepine.
(05 Mar 2000)
H2 antagonist <pharmacology> A class of anti-ulcer medication which work through the inhibition of basal and nocturnal gastric acid secretion by competitive inhibition of the action of histamine at histamine H2 receptor sites on the parietal cells.
Drugs of this type block gastric acid secretion and are therefore clinically useful in treating duodenal ulcers.
Examples include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid) and ranitidine (Zantac).
(27 Sep 1997)
insulin antagonist Something that opposes or fights the action of insulin. Insulin lowers the level of glucose (sugar) in the blood, whereas glucagon raises it, therefore, glucagon is an antagonist of insulin.
(09 Oct 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • contralateral
    ¹Ý´ëÂÊ¿¡ ÀϾ´Â;¹Ý´ëÂÊÀÇ À¯»çÇÑ ºÎºÐ°ú ¿¬µ¿ÇÏ´Â;´ëÃø¼ºÀÇ
  • antagonist
    Àû´ë
  • antagonist
    Àû´ëÀÚ;´ë¸³ÀÚ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á